Dr. Bianca Denise Santomasso, MD, PhD

Dr. Santomasso practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Santomasso's NPI, 1215164884, was assigned on June 22, 2009. Dr. Santomasso graduated from Weill Cornell Medicine in 2008. Dr. Santomasso holds New York license 2689151.

Dr. Santomasso's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Santomasso's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Santomasso to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Santomasso practices. Vendor and product names are available with a free account.

Neurology is Dr. Santomasso's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Santomasso is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Santomasso's licenses on file in 2 states: New York and New Jersey.

Dmand AI lists alzheimer's disease, epilepsy, fibromyalgia and chronic pain, migraine and chronic headache, mobility impairment, neuropathy, non-alzheimer's dementia (chronic) and sleep apnea among the conditions Dr. Santomasso treats.

CMS data shows 317 Medicare services from Dr. Santomasso across 8 procedure codes in 2024, for 149 Medicare patients. Medicare paid $32,887 for them.

CMS counts 149 Medicare patients who saw Dr. Santomasso in 2024. The largest group is 65 to 74, with 72 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 2.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Santomasso's median patient age at 70, with 59% women.

In 2024, Dr. Santomasso wrote 172 Medicare Part D claims for 39 patients. 91% of them were for generic drugs. CMS names the drug for 89 of them, across 4 drugs with 11 or more claims each, at $3,029 in total drug cost. In 2023, CMS named 98 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Santomasso for performance year 2024, reported as part of a group. Dr. Santomasso accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Santomasso as offering telehealth.

Dmand AI links 41 papers to Dr. Santomasso, published from 2009 to 2024. 2021 was the busiest year, with 6. The most frequent topics are Immunotherapy, Adoptive, Receptors, Chimeric Antigen and T-Lymphocytes. Dr. Santomasso has published most often in Blood Adv. Dr. Santomasso's most frequent co-authors are Miguel A. Perales, MD, Parastoo Bahrami Dahi, MD and Craig S. Sauter, MD.

CMS Open Payments shows 35 general payments to Dr. Santomasso from 8 drug and device companies from 2018 to 2024. Consulting fees make up the largest share, 97% of the total. Janssen Research & Development, LLC paid the most, $29,789.

Dr. Santomasso graduated from Weill Cornell Medicine in 2008.

Dr. Santomasso is in network with 12 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Massachusetts. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.